LARISSA II - CEPI RVFV Vaccine

LARISSA II (2023-2026).

In the LARISSA project, six consortium partners work with CEPI to develop and validate a novel vaccine against Rift Valley Fever. It is the first vaccine that potentially provides full protection with a single dose and has an optimal safety profile.

The Infectious Disease Epidemiology group at Wageningen University is part of the stage II trial of the LARISSA vaccine for Rift Valley Fever Virus. The postdoc leading the work is Mariken de Wit, supported by Logan Stuck, Quirine ten Bosch and myself.

Our part in the consortium is to explore strategy designs for a stage III clinical trial in Uganda or Kenya, which based on the local outbreak patterns, can be expected concluded within reasonable time, or if that is not possible, highlight the problem and suggest alternatives.

Find more about the LARISSA project at https://larissa.online 

Updated:

My background is in theoretical biology, and I have specialized in the analysis and modelling of the evolution, epidemiology and ecology of infectious diseases. At Wageningen University, I work on diseases that move between wildlife, livestock and humans.